scholarly journals A Case of Multiple Myeloma with Initial Symptoms of Amyloidosis of the Tongue and Buccal Mucosa

2018 ◽  
Vol 31 (2) ◽  
pp. 146-150
Author(s):  
SEIJI HYODO ◽  
YOSHINORI YONEMOTO ◽  
AYA UEMATSU ◽  
YUKI FUJITA ◽  
KOUICHI SAWAKI
Keyword(s):  
Multiple Myeloma ◽  
Buccal Mucosa ◽  
Initial Symptoms

scholarly journals Suggestive Diagnostic Process in a Case of Multiple Myeloma with Gastrointestinal Immunoglobulin Light-Chain Amyloidosis Accompanied by Protein-Losing Enteropathy

2021 ◽  
Vol 2021 ◽  
pp. 1-7
Author(s):  
Katsuya Endo ◽  
Takehito Ito ◽  
Jun Nomura ◽  
Keigo Murakami ◽  
Shiho Kondo ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Light Chain ◽  
Gastrointestinal Symptoms ◽  
Diagnostic Process ◽  
Al Amyloidosis ◽  
Immunoglobulin Light Chain ◽  
Protein Losing Enteropathy ◽  
Plasma Cell Neoplasm ◽  
Initial Symptoms ◽  
Sequential Diagnosis

Multiple myeloma is a type of plasma cell neoplasm that produces monoclonal immunoglobulin. Multiple myeloma is known to cause immunoglobulin light-chain (AL) amyloidosis, which frequently involves the kidney and heart. Bone pain or fractures caused by osteolytic lesions and physical disorders related to renal or cardiac AL amyloidosis are major initial symptoms in multiple myeloma. Multiple myeloma diagnosed from the gastrointestinal symptoms is rare. We report a case of an 80-year-old man with multiple myeloma accompanied by gastrointestinal AL amyloidosis and secondary protein-losing enteropathy. The diagnostic process was suggestive, in that diarrhea and refractory leg edema related to protein-losing enteropathy were the primary symptoms and the trigger for making a sequential diagnosis of gastrointestinal AL amyloidosis and underlying multiple myeloma. This case is highly suggestive, in that multiple myeloma with gastrointestinal AL amyloidosis should be considered one of the background diseases of protein-losing enteropathy.

scholarly journals Paraplegia Following Massage Therapy Intervention in a Patient With Undiagnosed Multiple Myeloma

2018 ◽  
Vol 24 (4) ◽  
pp. 313-315
Author(s):  
Ricardo Vieira Botelho ◽  
Matheus Fernandes De Oliveira ◽  
Rodolfo Casimiro Reis ◽  
Jânio Alves Ferreira ◽  
Sílvio Tenório Gameleira Filho ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Back Pain ◽  
Medical Diagnosis ◽  
Massage Therapy ◽  
Treatment Method ◽  
Alternative Therapies ◽  
Case Description ◽  
Time Loss ◽  
Initial Symptoms ◽  
Therapy Intervention

Introduction: Due to increased number of available alternative therapies to the treatment of back pain and sometimes a difficult access to specialized medical evaluations, there is a widespread use of alternative therapies for the treatment of back pain. Case Description: We describe a case with a catastrophic consequence of massage therapy in a patient with initial symptoms of back pain resulting in definitive paraplegia and discuss the needs for medical diagnosis for any treatment. Discussion and Conclusion: We discuss the potencial harms to the patient when initiating a questionable treatment method, which are late diagnosis, direct physical harm, interference with tradiotional treatments, financial harm and time loss. Alternative treatments are valuable tools to control refractory symptoms, especially pain. But we reinforce the need of adequate medical screening before performing therapies which may bring unwilling outcomes.

scholarly journals A Case of Buccal Mucosa and Tongue Amyloidosis Associated with Multiple Myeloma

2021 ◽  
Vol 27 (1) ◽  
pp. 26-32
Author(s):  
Mizuki ABE ◽  
Joji NOMURA ◽  
Shinnosuke NAKAMURA ◽  
Tetsuya IWAMOTO ◽  
Kaoru YAMAGUCHI ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Buccal Mucosa

Proteasome inhibitors as therapeutics

2005 ◽  
Vol 41 ◽  
pp. 205-218
Author(s):  
Constantine S. Mitsiades ◽  
Nicholas Mitsiades ◽  
Teru Hideshima ◽  
Paul G. Richardson ◽  
Kenneth C. Anderson
Keyword(s):  
Multiple Myeloma ◽  
Drug Class ◽  
Proteasome Inhibitors ◽  
Cell Cycle Regulators ◽  
Current State ◽  
Intracellular Mechanism ◽  
Ubiquitin Proteasome ◽  
Proteasome Pathway ◽  
Hodgkin's Lymphomas ◽  
Clinical Research Data

The ubiquitin–proteasome pathway is a principle intracellular mechanism for controlled protein degradation and has recently emerged as an attractive target for anticancer therapies, because of the pleiotropic cell-cycle regulators and modulators of apoptosis that are controlled by proteasome function. In this chapter, we review the current state of the field of proteasome inhibitors and their prototypic member, bortezomib, which was recently approved by the U.S. Food and Drug Administration for the treatment of advanced multiple myeloma. Particular emphasis is placed on the pre-clinical research data that became the basis for eventual clinical applications of proteasome inhibitors, an overview of the clinical development of this exciting drug class in multiple myeloma, and a appraisal of possible uses in other haematological malignancies, such non-Hodgkin's lymphomas.

Bone sialoprotein mRNA and protein expression in human multiple myeloma cell lines and patients

2000 ◽  
Vol 111 (4) ◽  
pp. 1118-1121 ◽  
Author(s):  
A. Bellahcene ◽  
I. Van Riet ◽  
C. de Greef ◽  
N. Antoine ◽  
M. F. Young ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Protein Expression ◽  
Cell Lines ◽  
Myeloma Cell ◽  
Bone Sialoprotein ◽  
Multiple Myeloma Cell ◽  
Human Multiple Myeloma ◽  
Mrna And Protein Expression

Controversies surrounding the clonogenic origin of multiple myeloma

2000 ◽  
Vol 110 (1) ◽  
pp. 240-241 ◽  
Author(s):  
Faith E. Davies ◽  
Andrew C. Rawstron ◽  
Roger G. Owen ◽  
Gareth J. Morgan
Keyword(s):  
Multiple Myeloma
Sign in / Sign up

Export Citation Format

Share Document